HIV相关伯基特淋巴瘤:美英联合分析的治疗结局
该国际分析纳入2008至2019年美英249例HIV相关伯基特淋巴瘤患者,中位随访4.5年,3年无进展生存率和总生存率分别为61%和66%。基线中枢神经系统受累、ECOG评分2-4、乳酸脱氢酶>5倍正常上限及>1个结外部位与较差生存独立相关。调整预后因素后,CODOX-M/IVAC方案与更长的无进展生存和总生存相关,HIV特征不再影响预后。
要点
- 3年无进展生存率61%,总生存率66%,美英两国结果相似。
- 基线中枢神经系统受累者3年无进展生存率仅36%,无受累者为69%。
- 调整预后因素后,CODOX-M/IVAC方案与更优的无进展生存和总生存相关。
核心结论
- 在当代治疗的HIV相关伯基特淋巴瘤患者中,HIV特征不再影响预后。
- 基线中枢神经系统受累、ECOG评分2-4、乳酸脱氢酶>5倍正常上限及>1个结外部位与较差的无进展生存和总生存独立相关。
- 调整上述预后因素后,CODOX-M/IVAC方案与更长的无进展生存和总生存相关。
研究设计与样本
- 国际多中心回顾性分析,纳入2008至2019年美国和英国共249例HIV相关伯基特淋巴瘤患者(美国140例,英国109例)。
- 中位随访4.5年,旨在识别预后因素和治疗结局。
主要发现
- 3年无进展生存率为61%(95%CI 55%至67%),3年总生存率为66%(95%CI 59%至71%),两国结果相似。
- 基线中枢神经系统受累者3年无进展生存率为36%,无受累者为69%(P < .001),且独立于一线治疗。
- 所有治疗中3年中枢神经系统复发发生率为11%;DA-EPOCH方案后复发发生率更高(亚分布风险比2.52;P = .03 vs 其他方案),且不因CD4计数100/mm3而不同。
- 多变量模型中与较差无进展生存独立相关的因素:ECOG评分2-4(HR 1.87;P = .007)、基线中枢神经系统受累(HR 1.70;P = .023)、乳酸脱氢酶>5倍正常上限(HR 2.09;P < .001)、>1个结外部位(HR 1.58;P = .043);这些变量对总生存同样显著。
- 调整预后因素后,CODOX-M/IVAC方案与更长的无进展生存(校正HR 0.45;P = .005)和总生存(校正HR 0.44;P = .007)相关。
临床怎么用
- 对HIV相关伯基特淋巴瘤患者,应评估基线中枢神经系统受累、ECOG评分、乳酸脱氢酶水平及结外部位数量以进行预后分层。
- 调整预后因素后,CODOX-M/IVAC方案与更优生存相关,可作为治疗选择参考。
- DA-EPOCH方案后中枢神经系统复发发生率较高,需关注中枢神经系统预防和监测。
局限性
- 回顾性分析设计可能存在选择偏倚和混杂因素。
- 原文未报告治疗方案的具体剂量、周期数及中枢神经系统预防的具体策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Data addressing prognostication in patients with HIV related Burkitt lymphoma (HIV-BL) currently treated remain scarce. We present an international analysis of 249 (United States: 140; United Kingdom: 109) patients with HIV-BL treated from 2008 to 2019 aiming to identify prognostic factors and outcomes. With a median follow up of 4.5 years, the 3-year progression-free survival (PFS) and overall survival (OS) were 61% (95% confidence interval [CI] 55% to 67%) and 66% (95%CI 59% to 71%), respectively, with similar results in both countries. Patients with baseline central nervous system (CNS) involvement had shorter 3-year PFS (36%) compared to patients without CNS involvement (69%; P < .001) independent of frontline treatment. The incidence of CNS recurrence at 3 years across all treatments was 11% with a higher incidence observed after dose-adjusted infusional etoposide, doxorubicin, vincristine, prednisone, cyclophosphamide (DA-EPOCH) (subdistribution hazard ratio: 2.52; P = .03 vs other regimens) without difference by CD4 count 100/mm3. In multivariate models, factors independently associated with inferior PFS were Eastern Cooperative Oncology Group (ECOG) performance status 2-4 (hazard ratio [HR] 1.87; P = .007), baseline CNS involvement (HR 1.70; P = .023), lactate dehydrogenase >5 upper limit of normal (HR 2.09; P < .001); and >1 extranodal sites (HR 1.58; P = .043). The same variables were significant in multivariate models for OS. Adjusting for these prognostic factors, treatment with cyclophosphamide, vincristine, doxorubicin, and high-dose methotrexate, ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) was associated with longer PFS (adjusted HR [aHR] 0.45; P = .005) and OS (aHR 0.44; P = .007). Remarkably, HIV features no longer influence prognosis in contemporaneously treated HIV-BL.
引用
- Alderuccio JP, Olszewski AJ, Evens AM, et al. HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Blood Adv. 2021. PMID: 34283175. doi:10.1182/bloodadvances.2021004458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。